axicabtagene ciloleucel + tisagenlecleucel

Axicabtagene ciloleucel + tisagenlecleucel is a theoretical combination of two autologous CD19-directed CAR-T cell therapies used individually for relapsed or refractory B-cell malignancies. Axicabtagene ciloleucel (axi-cel) is a CD28-costimulated, second-generation CAR-T developed by Kite Pharma/Gilead and approved for adults with relapsed or refractory large B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, in second-line and later settings.[2][6][10] Tisagenlecleucel (tisa-cel) is a 4-1BB-costimulated CD19-directed CAR-T developed by Novartis and approved for pediatric and young adult B-cell acute lymphoblastic leukemia as well as adults with relapsed or refractory large B-cell lymphomas after at least two prior lines of systemic therapy.[4][8][14] Both products function by redirecting autologous T cells to recognize and kill CD19-positive B cells through CAR-mediated activation, expansion, and cytotoxicity, and both carry boxed warnings for cytokine release syndrome and neurotoxicity.[2][4][10][11] There is no established clinical product or regulatory approval for concomitant or sequential administration as a fixed combination of axicabtagene ciloleucel and tisagenlecleucel; this construct should therefore be regarded as a conceptual combination of two separate, individually approved CAR-T products.[1][3][5][7]